MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9

被引:177
作者
Dong, Zhuo [1 ]
Zhong, Zhiwei [1 ]
Yang, Lihua [1 ]
Wang, Shaomin [2 ]
Gong, Zhaohui [1 ]
机构
[1] Ningbo Univ, Sch Med, Inst Biochem & Mol Biol, Zhejiang Prov Key Lab Pathophysiol, Ningbo 315211, Peoples R China
[2] Ningbo Univ, Sch Med, Affiliated Hosp, Dept Oncol, Ningbo 315211, Zhejiang, Peoples R China
关键词
miR-31; ABCB9; Cisplatin resistance; Apoptosis; Non-small cell lung cancer; MULTIDRUG-RESISTANCE; CONFERS RESISTANCE; CHEMOTHERAPY; MIR-31; SENSITIVITY; EXPRESSION; LANDSCAPE; MECHANISM; CARCINOMA; MIGRATION;
D O I
10.1016/j.canlet.2013.09.034
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Alterations in microRNA (miRNA) expression have been found to be involved in tumor growth and response to chemotherapy. However, the possible role of miR-31 in cisplatin (DDP) resistance in non-small cell lung cancer (NSCLC) remains unclear. In this study, we identified a DDP-sensitive and a DDP-resistant cell line from four candidate human NSCLC cell lines. Notably, we found that miR-31 was significantly upregulated in the DDP-resistant cell line compared with its level in the DDP-sensitive cell line. As a result, miR-31 overexpression induced DDP resistance in the DDP-sensitive cell line, and miR-31 knockdown rescued DDP sensitivity in the DDP-resistant cell line. Interestingly, miR-31 was inversely correlated with the expression of the drug resistance gene ABCB9. The luciferase activity assay showed that miR-31 directly targets the 3'UTR of ABCB9, which is known to play a crucial role in drug resistance. Mechanistically, we showed that miR-31 confers DDP-induced apoptosis and that inhibition of ABCB9 is required for DDP resistance. The data demonstrate that miR-31 exerts an anti-apoptotic effect most likely through the inhibition of ABCB9 and thus provide a novel strategy involving the use of miR-31 as a potential target in NSCLC chemotherapy. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:249 / 257
页数:9
相关论文
共 39 条
[1]
MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[2]
Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells [J].
Bhatnagar, N. ;
Li, X. ;
Padi, S. K. R. ;
Zhang, Q. ;
Tang, M-S ;
Guo, B. .
CELL DEATH & DISEASE, 2010, 1 :e105-e105
[3]
MicroRNAs modulate the chemosensitivity of tumor cells [J].
Blower, Paul E. ;
Chung, Ji-Hyun ;
Verducci, Joseph S. ;
Lin, Shili ;
Park, Jong-Kook ;
Dai, Zunyan ;
Liu, Chang-Gong ;
Schmittgen, Thomas D. ;
Reinhold, William C. ;
Croce, Carlo M. ;
Weinstein, John N. ;
Sadee, Wolfgang .
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (01) :1-9
[4]
Role of MicroRNAs in Lung Cancer MicroRNA Signatures in Cancer Prognosis [J].
Boeri, Mattia ;
Pastorino, Ugo ;
Sozzi, Gabriella .
CANCER JOURNAL, 2012, 18 (03) :268-274
[5]
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC [J].
Chang, Alex .
LUNG CANCER, 2011, 71 (01) :3-10
[6]
Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases [J].
Chen, Zhe-Sheng ;
Tiwari, Amit K. .
FEBS JOURNAL, 2011, 278 (18) :3226-3245
[7]
miR-21 and miR-31 Converge on TIAM1 to Regulate Migration and Invasion of Colon Carcinoma Cells [J].
Cottonham, Charisa L. ;
Kaneko, Satoshi ;
Xu, Lan .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (46) :35293-35302
[8]
Tuning the Cellular Trafficking of the Lysosomal Peptide Transporter TAPL by its N-terminal Domain [J].
Demirel, Oezlem ;
Bangert, Irina ;
Tampe, Robert ;
Abele, Rupert .
TRAFFIC, 2010, 11 (03) :383-393
[9]
The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas [J].
Di Lisio, Lorena ;
Martinez, Nerea ;
Montes-Moreno, Santiago ;
Piris-Villaespesa, Miguel ;
Sanchez-Beato, Margarita ;
Piris, Miguel A. .
BLOOD, 2012, 120 (09) :1782-1790
[10]
microRNA regulation of cell viability and drug sensitivity in lung cancer [J].
Du, Liqin ;
Pertsemlidis, Alexander .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (09) :1221-1239